REG - GlaxoSmithKline PLC - Transfer of Treasury Shares

GSKAnnouncement

14/02/2022 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220214:nRSN6213Ba&default-theme=true

RNS Number : 6213B  GlaxoSmithKline PLC  14 February 2022

GlaxoSmithKline plc

(the 'Company')

 

Transfer of Treasury Shares

 

 

On 10 February 2022, the Company transferred 50,300,000 ordinary shares of 25
pence each ("Ordinary Shares") that were held by the Company in treasury
("Treasury Shares") of which (a) 34,500,000 Ordinary Shares were transferred
to the Company's Jersey resident trust, the GlaxoSmithKline Employee Trust
(the "Jersey Trust"), and (b) 15,800,000 Ordinary Shares were transferred to
JPMorgan Chase Bank, N.A. the depositary of the Company's American depositary
receipts ("ADR") programme, to procure the issuance and transfer of
7,900,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the "US
Trust"), such Ordinary Shares and those ADRs to be used to satisfy awards
granted under the Company's Deferred Annual Bonus Plan, Performance Share Plan
and Share Value Plan. The consideration received from the trustee of the
Jersey Trust, of £16.208 per Ordinary Share, was funded by a loan from
GlaxoSmithKline Services Unlimited, and the consideration received from the
trustee of the US Trust of $44.260 per ADR, representing $22.130 per Ordinary
Share, was funded by a contribution to the US Trust from GlaxoSmithKline LLC.

 

Following the transfer and as at 11 February 2022, the Company's issued share
capital consisted of 5,388,496,258 Ordinary Shares, of which 304,905,950 were
held as Treasury Shares.

 

Therefore, the total number of voting rights in the Company is 5,083,590,308.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

V A Whyte

Company Secretary

 

14 February 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSZZGMZFDFGZZM